Tideglusib for people with early ALS
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This Phase 2 study tests tideglusib to see if it helps slow or improve amyotrophic lateral sclerosis (ALS). You may be eligible if you have early-stage ALS with preserved breathing ability and certain stable treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18 years) with ALS diagnosed by standard criteria
- Your ALS has been present for less than 18 months
- Your breathing test result (vital capacity) is above 60% of normal
- You are either on stable riluzole and/or stable edaravone (or you don’t take them)
- You can understand the study and give informed consent
- You have not joined another research study in the last 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
This Phase 2 study tests whether dazucorilant can slow or improve outcomes in people with amyotrophic lateral sclerosis (ALS) who are likely to progress more quickly. You may be able to join if you meet specific ALS type and risk-score requirements and your health tests and medications fit the study rules.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.